Corporate ActionMay 18, 2026, 11:06 AM
Tarsier Pharma Plans IPO of 5M Shares at $8-10; 10-for-1 Stock Split
AI Summary
Tarsier Pharma Ltd. filed an amendment to its F-1 registration statement, detailing plans for an initial public offering of 5,000,000 ordinary shares. The anticipated price range is $8.00 to $10.00 per share, with an assumed midpoint of $9.00. Prior to the offering, the company intends to effect a 10-for-1 forward stock split. Tarsier Pharma has applied to list its shares on the NYSE under "TARX" and has secured a Special Protocol Assessment (SPA) agreement with the FDA for its upcoming pivotal Phase 3 trial (Tarsier-04) for TRS01, with IOP safety as the primary endpoint.
Key Highlights
- Initial Public Offering of 5,000,000 ordinary shares planned.
- Anticipated IPO price range is $8.00 to $10.00 per share.
- 10-for-1 forward stock split to be effected prior to the offering.
- Applied to list ordinary shares on NYSE under the symbol "TARX".
- Underwriter has an option to purchase an additional 750,000 ordinary shares.
- FDA granted Special Protocol Assessment (SPA) for pivotal Phase 3 trial (Tarsier-04) for TRS01.
- Tarsier-04 primary endpoint is IOP safety (superiority to steroids).
- Estimated U.S. market for non-infectious anterior uveitis with uveitic glaucoma is over $5 billion.
Price Impact